HNPCC-associated small bowel cancer: Clinical and molecular characteristics

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Karsten Schulmann - , Ruhr University Bochum (Author)
  • Frank E. Brasch - , Ruhr University Bochum (Author)
  • Erdmute Kunstmann - , Ruhr University Bochum (Author)
  • Christoph Engel - , Leipzig University (Author)
  • Constanze Pagenstecher - , University of Bonn (Author)
  • Holger Vogelsang - , Technical University of Munich (Author)
  • Stefan Krüger - , Department of Surgical Research (Author)
  • Tilman Vogel - , Heinrich Heine University Düsseldorf (Author)
  • Hanns Peter Knaebel - , Heidelberg University  (Author)
  • Josef Rüschoff - , Klinikum Kassel GmbH (Author)
  • Stephan A. Hahn - , Ruhr University Bochum (Author)
  • Magnus V. Knebel-Doeberitz - , Heidelberg University  (Author)
  • Gabriela Moeslein - , Heinrich Heine University Düsseldorf (Author)
  • Stephen J. Meltzer - , University of Maryland, Baltimore (Author)
  • Hans K. Schackert - , Department of Surgical Research (Author)
  • Christiane Tympner - , Ludwig Maximilian University of Munich (Author)
  • Elisabeth Mangold - , University of Bonn (Author)
  • Wolff Schmiegel - , Ruhr University Bochum (Author)

Abstract

Background & Aims: The risk for small bowel cancer (SBC) is significantly increased in hereditary nonpolyposis colorectal cancer (HNPCC). HNPCC-associated SBCs are poorly characterized. Methods: Thirty-two SBCs were characterized according to clinical, pathologic, and germline mutation data. Histomorphologic characteristics, microsatellite instability (MSI) testing, mismatch repair (MMR) protein expression, and frameshift mutations of 7 coding mononucleotide repeats were investigated in 17 SBCs. Results: Median age at diagnosis was 39 years. Fifty percent of SBCs were located in the duodenum. The Amsterdam criteria were fulfilled in 50% of patients; 45% of patients had no personal history of previous malignancies. Two patients had a positive family history for SBC. Pathogenic germline mutations were identified in 81%; high MSI was detected in 95% and loss of MMR protein expression in 89% of cases. TGFBR2, BAX, MSH3, MSH6, ACVR2, AIM2, and SEC63 frameshift mutations were detected in 69%, 59%, 59%, 35%, 82%, 56%, and 56%, respectively. An expansive growth pattern of the tumor border and an intense intratumoral lymphocytic infiltrate were present in 75%, respectively. Conclusions: HNPCC-associated SBC often manifests at a young age and may be the first disease manifestation. Endoscopy may detect 50% of tumors. Considering recent data on gastric cancer, we propose endoscopic screening of mutation carriers starting at 30 years of age because clinical criteria cannot define a high-risk group. In addition, our study shows that histopathologic criteria, MSI, and MMR immunohistochemistry are often similar to these features in HNPCC.

Details

Original languageEnglish
Pages (from-to)590-599
Number of pages10
JournalGastroenterology
Volume128
Issue number3
Publication statusPublished - Mar 2005
Peer-reviewedYes

External IDs

PubMed 15765394

Keywords

Sustainable Development Goals

ASJC Scopus subject areas